These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21350000)

  • 1. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.
    Sano D; Fooshee DR; Zhao M; Andrews GA; Frederick MJ; Galer C; Milas ZL; Morrow PK; Myers JN
    Head Neck; 2011 Mar; 33(3):349-58. PubMed ID: 20629091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
    Klein JD; Christopoulos A; Ahn SM; Gooding WE; Grandis JR; Kim S
    Head Neck; 2012 Sep; 34(9):1269-76. PubMed ID: 22307735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
    Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
    Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
    Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
    Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
    Ekshyyan O; Rong Y; Rong X; Pattani KM; Abreo F; Caldito G; Chang JK; Ampil F; Glass J; Nathan CO
    Mol Cancer Ther; 2009 Aug; 8(8):2255-65. PubMed ID: 19625495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
    Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
    Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
    Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
    Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
    Kitamura S; Maeda T; Yanagi T
    Biochem Biophys Res Commun; 2020 Oct; 531(3):396-401. PubMed ID: 32800552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
    Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
    Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
    Papadimitrakopoulou VA; Frank SJ; Cohen EW; Hirsch FR; Myers JN; Heymach JV; Lin H; Tran HT; Chen CR; Jimeno A; Nedzi L; Vasselli JR; Lowe ES; Raben D
    Head Neck; 2016 Mar; 38(3):439-47. PubMed ID: 25352401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.
    Sano D; Kawakami M; Fujita K; Kimura M; Yamashita Y; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Feb; 17(2):289-95. PubMed ID: 17203163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
    McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
    Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.